Skip To Main Content

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

Beyfortus® ▼(nirsevimab): effectiveness and public health impact in the real world

Gaucher disease in children

DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3

Real-World Evidence and Phase IV studies in CRSwNP

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.

Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities

Breaking the Barrier: How to Manage Hypoglycaemia Fear in Diabetes Care

Reframing the Insulin Conversation: Helping People With Type 2 Diabetes to Embrace Life

FLUNITY-HD : the largest individually randomised influenza vaccine effectiveness study of its kind.

FLUNITY-HD is the largest individually randomised influenza vaccine effectiveness study, with nearly half a million older adults across multiple seasons.1

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Deliver-T (RWE Study): New Findings on Toujeo® for T2D Management Following Dual GIP/GLP-1 RA Therapy

IL-4 et IL-13 : au cœur des mécanismes de l’inflammation de type 2

The story of the Beta Cells and their role in autoimmune Type 1 Diabetes